Key highlights
- Placebo-adjusted mean improvement of 45% in EASI scores for atopic dermatitis patients at day 57
- ATI-052 treatment arm achieved 62% mean EASI improvement from baseline by week 10
- Single dose demonstrated rapid improvements in airway inflammation and lung function for asthma patients
- Estimated cash and marketable securities of $204.6 million as of September 30, 2026
- Phase 2b development for eosinophilic esophagitis scheduled to commence in early 2027
Clinical Trial Outcomes
Aclaris Therapeutics reported that ATI-052 met its primary objective in two separate Phase 1b proof-of-concept trials. In the atopic dermatitis study, patients receiving five weekly 480 mg doses experienced significant skin clearance, with clinical effects maintained through week 10. In the asthma cohort, the bispecific antibody achieved rapid improvements in lung function across a diverse patient population. The company estimates its cash, cash equivalents, and marketable securities at approximately $204.6 million as of September 30, 2026, providing liquidity to advance its revised clinical roadmap focused on eosinophilic esophagitis.
Strategic Significance
- Simultaneous targeting of TSLP and IL-4Ra provides potential synergistic efficacy over single-target monotherapies
- Absence of conjunctivitis addresses a common safety concern seen in competing IL-4Ra inhibitor treatments
- Strategic pivot to eosinophilic esophagitis prioritizes an indication with high unmet medical need
- Proof-of-concept validation supports the potential for broad utility across multiple immuno-inflammatory conditions
- The results demonstrate early durability and normalization of the immune proteome in heterogeneous disease states
Business and Pipeline Overview
Pennsylvania-based Aclaris Therapeutics is a clinical-stage biopharmaceutical firm specializing in immuno-inflammatory disease treatments. The company pipeline includes ATI-052 and modzatinib, an oral ITK/JAK3 inhibitor currently being evaluated for lichen planus under FDA Fast Track designation. Aclaris recently expanded its portfolio through an exclusive global license agreement with Biosion for ATI-052 and bosakitug. The firm maintains a disciplined capital management strategy, with current cash reserves expected to fund operations and pipeline milestones through the end of 2028.
Financial and Sector Context
Aclaris reported preliminary cash and marketable securities of approximately $204.6 million as of September 30, 2026, an increase from $170.6 million at the end of the second quarter. This growth was assisted by at-the-market equity sales yielding $40.2 million in gross proceeds. The biotechnology sector continues to explore bispecific antibodies to achieve superior efficacy in Th2-mediated diseases. Upcoming milestones for Aclaris include a Phase 2 clinical readout for the anti-TSLP monoclonal antibody bosakitug in moderate-to-severe atopic dermatitis, which is expected in the fourth quarter of 2026.
Down 4.9% since our story on 27 Oct: $3.79 when we broke it → $3.60 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $3.48 |
|---|---|
| 20 Oct | $3.77 |
| 21 Oct | $3.81 |
| 22 Oct | $3.83 |
| 23 Oct | $3.75 |
| 26 Oct | $3.79 |
| 27 Oct | $3.79 |
| 28 Oct | $3.96 |
| 29 Oct | $3.99 |
| 30 Oct | $3.97 |
| 2 Nov | $3.80 |
| 3 Nov | $3.74 |
| 4 Nov | $3.68 |
| 5 Nov | $3.61 |
| 6 Nov | $3.90 |
| 9 Nov | $4.24 |
| 10 Nov | $4.15 |
| 11 Nov | $4.34 |
| 12 Nov | $4.00 |
| 13 Nov | $3.92 |
| 16 Nov | $3.60 |
Management Perspective
“These strong results convey the art of the possible with this bispecific mechanism in heterogeneous diseases across diverse patient populations and support that this is a potent, broadly acting compound with potential best-in-class activity.”
| Date | Announcement | Amount |
|---|---|---|
| 06 Aug 2026 | FDA Fast Track designation granted for modzatinib (ATI-2138) in moderate to severe lichen planusSource: investor.aclaristx.com | – |
| 28 Apr 2026 | Positive full topline Phase 1a results for ATI-052 and selection of lichen planus as lead indication for ATI-2138Source: investor.aclaristx.com | – |
| 29 Jul 2025 | Positive topline results from Phase 2a trial of oral ITK/JAK3 inhibitor ATI-2138 in atopic dermatitisSource: globenewswire.com | – |
| 18 Nov 2024 | Securities purchase agreement for private placement of common stockSource: investor.aclaristx.com | $80.0 Million |
| 18 Nov 2024 | Exclusive global license agreement with Biosion for BSI-045B (bosakitug) and BSI-502 (ATI-052)Source: SEC filing | $40.7 Million |
Management commentary
“These strong results convey the art of the possible with this bispecific mechanism in heterogeneous diseases across diverse patient populations and support that this is a potent, broadly acting compound with potential best-in-class activity.”
| Share price | $3.79 |
|---|---|
| Market cap | $558M |
| Revenue (annual) | $8M |
| 1-month price change | -29.55% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Aclaris Therapeutics, Inc. announcing positive Phase 1b results for ATI-052.
Track Aclaris Therapeutics, Inc. live
Get the next Aclaris Therapeutics, Inc. SEC filing seconds after it lands.

